July 17, 2020
Joel L. Cohen, MD; and Conor Gallagher, PhD
Ever wonder about the differences in formulation and manufacture of botulinum neurotoxins? Curious about the trials that support approval? In this edition of Scientifically Speaking, Joel L. Cohen, MD gets the answers to these questions and more from Conor Gallagher, PhD, Head of Medical Affairs, Revance Therapeutics, Inc.